Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis-Reference-Cited by-同舟云学术

Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis

Published:2022-11-02 Issue:22 Volume:65 Page:15000-15013
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Futatsugi Kentaro¹^ORCID,Cabral Shawn²,Kung Daniel W.²^ORCID,Huard Kim¹,Lee Esther¹^ORCID,Boehm Markus¹^ORCID,Bauman Jonathan²,Clark Ronald W.³,Coffey Steven B.²,Crowley Collin³,Dechert-Schmitt Anne-Marie²,Dowling Matthew S.²^ORCID,Dullea Robert³,Gosset James R.¹,Kalgutkar Amit S.¹^ORCID,Kou Kou³,Li Qifang²,Lian Yajing²,Loria Paula M.²,Londregan Allyn T.²^ORCID,Niosi Mark²,Orozco Christine²,Pettersen John C.⁴,Pfefferkorn Jeffrey A.³,Polivkova Jana²,Ross Trenton T.³,Sharma Raman²,Stock Ingrid A.²,Tesz Gregory³,Wisniewska Hanna²,Goodwin Bryan³,Price David A.¹

Affiliation:

1. Pfizer Inc. Medicine Design, 1 Portland Street, Cambridge, Massachusetts 02139, United States

2. Pfizer Inc. Medicine Design, Eastern Point Road, Groton, Connecticut 06340, United States

3. Pfizer Inc. Internal Medicine Research Unit, 1 Portland Street, Cambridge, Massachusetts 02139, United States

4. Pfizer Inc. Drug Safety R&D, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01200

Reference42 articles.

1. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease

2. Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation

3. Human Fatty Liver Disease: Old Questions and New Insights

4. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose

5. Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined structure-based virtual screening and machine learning approach for the identification of potential dual inhibitors of ACC and DGAT2;International Journal of Biological Macromolecules;2024-10

2. Bioactivation and reactivity research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-17

3. An update on lipophilic efficiency as an important metric in drug design;Expert Opinion on Drug Discovery;2024-06-26

4. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?;Expert Opinion on Pharmacotherapy;2024-06-12

5. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics;Lipids in Health and Disease;2024-04-02